Azamian Bobak R. 4

4 · Tarsus Pharmaceuticals, Inc. · Filed Mar 17, 2026

AI-generated summary of this filing

Updated Mar 17, 2026

Tarsus CEO Bobak Azamian Receives 66,274 Shares (RSU Settlement)

What Happened

Bobak R. Azamian (President/CEO and Board Chair) had 66,274 restricted stock units (RSUs convert/settle into shares) on March 15, 2026. The filing shows 66,274 shares issued (acquired) and the same total split into four derivative "disposed" line items (11,300; 16,975; 23,121; 14,878) reported at $0.00.
The acquisition line is listed as an RSU settlement (derivative conversion). The $0.00 disposition entries indicate shares were transferred/withheld (commonly for taxes or related obligations), not sold for cash. No cash proceeds or market-sale prices are reported.

Key Details

Transaction date: March 15, 2026; Form 4 filed March 17, 2026 (timely filing).
Reported activity: 66,274 shares issued on RSU settlement; 11,300 + 16,975 + 23,121 + 14,878 shares reported disposed at $0.00.
Prices/values: Acquisition price listed as N/A; dispositions reported at $0.00 (no cash proceeds shown).
Shares owned after transaction: not provided in the supplied data.
Notable footnotes: shares issued pursuant to vested RSUs (F1); reporting person is trustee of the Bobak Azamian Living Trust (F2); each RSU converts to one share (F3); the RSUs originate from grants under the 2020 Stock Plan with typical 25% annual vesting schedules (grants from 2022–2025 per F4–F7).

Context

These entries reflect RSU settlement and subsequent withholding/transfers (the $0.00 dispositions are typical when shares are retained to satisfy tax withholding or similar obligations), not open-market sales or purchases.
This is an award/vesting event rather than a buy or sell decision; it does not by itself signal insider sentiment about the company.

Form 4

Period: 2026-03-15

DirectorPresident/CEO and Board Chair

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-03-15+66,274→ 68,024 total
Exercise/Conversion
Restricted Stock Units
[F3][F4]
2026-03-15−11,300→ 0 total
→ Common Stock (11,300 underlying)
Exercise/Conversion
Restricted Stock Units
[F3][F5]
2026-03-15−16,975→ 16,975 total
→ Common Stock (16,975 underlying)
Exercise/Conversion
Restricted Stock Units
[F3][F6]
2026-03-15−23,121→ 46,243 total
→ Common Stock (23,121 underlying)
Exercise/Conversion
Restricted Stock Units
[F3][F7]
2026-03-15−14,878→ 44,634 total
→ Common Stock (14,878 underlying)

Holdings

Footnotes (7)

[F1]The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").
[F2]The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares.
[F3]Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock.
[F4]RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs vested on March 15th of each of 2023, 2024, 2025 and 2026.
[F5]RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service.
[F6]RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service.
[F7]RSUs granted on March 5, 2025, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service.

Signature

/s/ Jeffrey Farrow, Attorney-in-Fact|2026-03-17

1 file